Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 11/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050866 | 0.82 | CYP1A2 (0.38) | CYP1A2ALDH1A1SMN1; SMN2TDP1MEN1 | |
| SCHEMBL25334109 | 0.78 | CYP1A2 (0.41) | CYP1A2ALDH1A1SMN1; SMN2PIN1TDP1 | |
| SCHEMBL21050736 | 0.75 | CYP1A2 (0.44) | CYP1A2ALDH1A1SMN1; SMN2PIN1TDP1 | |
| SCHEMBL21050782 | 0.75 | CYP1A2 (0.41) | CYP1A2ALDH1A1SMN1; SMN2PIN1TDP1 | |
| SCHEMBL25795346 | 0.74 | CYP1A2 (0.52) | CYP1A2ALDH1A1SMN1; SMN2TDP1MEN1 | |
| SCHEMBL3590495 | 0.74 | TDP1 (0.41) | CYP1A2ALDH1A1SMN1; SMN2PIN1TDP1 | |
| SCHEMBL109594 | 0.71 | CYP1A2 (0.49) | CYP1A2ALDH1A1SMN1; SMN2PIN1TDP1 | |
| SCHEMBL31093759 | 0.71 | CYP1A2 (0.41) | CYP1A2ALDH1A1SMN1; SMN2PIN1TDP1 | |
| SCHEMBL5250298 | 0.71 | PIN1 (0.39) | CYP1A2ALDH1A1PIN1TDP1MEN1 | |
| SCHEMBL28818247 | 0.71 | TDP1 (0.41) | CYP1A2ALDH1A1SMN1; SMN2PIN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597405-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-24 | — | — | US | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | CYP1A2 106/4885ALDH1A1 26/4885SMN1; SMN2 576/4885 |
| US-10597405-B2 | Chemical compounds | MKI67, CCNI, MCL1 | CYP1A2 106/4885ALDH1A1 26/4885SMN1; SMN2 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.